Search for:
Search for:
Healthcare Professionals
Publications
Contact
News
Español
Magazine
Radio
*
INFÓRMESE
¿Qué es EM?
Un trastorno neurológico crónico que afecta el sistema nervioso central, compuesto por el cerebro...
Más detalles
MATERIALES EDUCATIVOS
PREGUNTAS COMUNES
Lending Library
Symptoms
Treatment Options
Additional Resources
INVESTIGACIÓN
MS Awareness Month
DONAR
OBTENGA AYUDA
Programa de Salud y Bi...
Obtenga materiales educativos y referencias así como también la oportunidad de participar en...
Más información
Grants & Programs
Awareness Campaigns
GRUPOS DE APOYO
Events
Lending Library
Additional Resources
PARTICIPE
Mes de Concientización...
Una campaña anual a nivel nacional con objetivos para promover la comprensión de la EM y ayudar a...
Más información
Advocacy
COMPRAS A SOCIOS
VOLUNTARIO
Businesses
MS Research Trials
Outreach
Supporter Program
Awareness Campaigns
Host an Event
Events
MS Focus on Fashion
The inaugural MS Focus on Fashion, will take place on Nov. 6, in Dania Beach, Fla.
Learn More
Events Calendar
Health & Wellness
Fundraisers
Support
Web & Teleconferences
MS Education
Host an Event
QUIÉNES SOMOS
Programas y Subvenciones
Más detalles
Overview
Press Room
LIDERAZGO
Healthcare Advisory Board
ESTADOS FINANCIEROS
NUESTRA MISIÓN
Careers at MS Focus
Affiliations
PROGRAMA DE TECNOLOGÍA...
El Programa de Tecnología de Asistencia brinda información y financiamiento para dispositivos que...
/Get-Help/MSF-Programs-Grants/Assistive-Technology-Program
Shop
Privacy
Terms of Use
Site Map
New study uncovers therapeutic inertia in the treatment of women with MS
septiembre 27, 2024
A study has revealed significant therapeutic inertia in the treatment of women with multiple sclerosis, highlighting gender disparities that could affect long-term health outcomes for women of childbearing age. The findings suggest that concerns related to pregnancy may lead to delayed or reduced use of disease-modifying treatments, even before pregnancy becomes a consideration.
In an extensive analysis of 22,657 patients with relapsing MS who were on the French MS registry, researchers found more than a median follow-up of 11.6 years women had a significantly lower probability of being treated with any DMT and were even less likely to be prescribed high-efficacy DMTs.
The difference in DMT usage varied across both different treatments and over time. Teriflunomide, fingolimod, and anti-CD20 therapies were significantly underused throughout their entire availability. Interferon and natalizumab were initially used less frequently, but their usage equalized over time. In contrast, glatiramer acetate and dimethyl fumarate were initially used equally between genders, but eventually became more commonly prescribed to women.
The study further highlighted the disparity in treatment emerged after two years of disease duration for DMTs and as early as one year for HEDMTs. Interestingly, this gender-based treatment gap did not significantly vary with patient age, indicating therapeutic inertia may persist regardless of a woman’s stage in life.
Both neurologists and patients contribute to this therapeutic inertia, many taking a precautionary approach and avoiding these treatments. According to the researchers, neurologists might be hesitant to prescribe DMTs, particularly if they are not comfortable with managing pregnancy-related issues. At the same time, women, understandably, do not want to take any risks for their child or pregnancy. Their primary concerns are congenital malformations, fetal loss, and fetal growth disorders. Women will also experience discomfort if their neurologist seems uncertain.
Moving forward, the research team plans to delve deeper into the factors contributing to this therapeutic inertia, with a focus on improving treatment strategies that prioritize both the long-term health of women with MS and their reproductive goals.
The findings were presented at ECTRIMS 2024.
[Error loading the control 'FeaturedNews', check event log for more details]